Vitiliginous Choroiditis

Vitiliginous choroiditis is a long-lasting inflammation inside the back of the eye. It mainly affects the choroid (the layer that feeds the retina) and the retina (the light-sensing layer). The disease causes many pale, creamy spots in the back of the eye. The spots are often oval and point outward from the optic nerve like scattered birdshot. Both eyes are usually involved. The disease is rare. It most often appears in middle-aged adults. It can slowly harm night vision, contrast vision, and the visual field. If not controlled, it may lead to permanent vision loss. Doctors now know this condition is strongly linked to a tissue-type gene called HLA-A29. Because of this, many experts prefer the name HLA-A29 uveitis or birdshot chorioretinopathy. PMC+4PMC+4American Academy of Ophthalmology+4

Vitiliginous choroiditis—also called birdshot chorioretinopathy—is a rare, long-lasting inflammation in the back of the eye. It affects the choroid (the blood-rich layer under the retina) and the retina itself. Doctors see many pale, cream-colored spots in a “birdshot” pattern at the back of the eye. People may have blurry vision, floaters, trouble seeing at night, glare, and color changes. The condition is strongly linked to an immune marker called HLA-A29, which suggests the immune system is attacking the eye by mistake. Over time, inflammation can damage the retina and macula and cause vision loss if not treated early and carefully. Modern care focuses on calming the inflammation, protecting the macula, preventing relapses, and preserving vision with a mix of medicines and sometimes tiny steroid implants placed inside the eye. (Overview sources: EyeWiki; StatPearls; NIH GARD; Orphanet; peer-review reviews.) PMC+4EyeWiki+4NCBI+4

The white lesions you can see on exam are only part of the story. There is also inflammation in the retinal vessels and the central retina. This inflammation can cause cystoid macular edema (swelling of the retina at the center of sight), thinning of photoreceptors, and reduced electrical responses on eye function tests. Because of these silent changes, patients can feel their vision is worse even when reading-chart vision looks okay early on. Ajo+2BioMed Central+2

---

Other names

Doctors and articles may use several names for the same disease:

• Birdshot chorioretinopathy

• Birdshot retinochoroidopathy

• Birdshot retinochoroiditis

• HLA-A29 uveitis / HLA-A29 birdshot

• Vitiliginous choroiditis (older term)

These names refer to the same clinicopathologic entity, with “vitiliginous” describing the pale depigmented spots and “birdshot” describing their scattered look. Modern sources often include “HLA-A29” to stress the genetic link. Orpha+2PMC+2

---

Types

There is no strict, universal “type” list like in some other diseases, but clinicians often talk about forms or phases that help plan care:

1. Classic HLA-A29–positive birdshot. This is the common form. Patients have the typical cream-colored lesions and test positive for HLA-A29. PMC

2. Birdshot-like, HLA-A29–negative disease. Rarely, a patient has a similar look but tests negative for HLA-A29. Doctors then search very carefully for other causes and may call it “birdshot-like chorioretinopathy.” PMC

3. Retina-dominant vs choroid-dominant pattern. Some patients show stronger retinal involvement (vasculitis, macular edema) while others show many choroidal lesions with fewer retinal signs. This “dual and partly independent” retinal and choroidal process is well described. PMC

4. Active (inflamed) vs quiet (inactive) phase. In the active phase, imaging shows leakage and dark choroidal dots; in quieter phases, lesions look more “punched out” and tests improve but often do not return to normal. Ajo

5. Early vs late disease. Early disease may have near-normal reading-chart vision but reduced contrast sensitivity, night vision, and abnormal electroretinogram. Late disease can show field loss, vessel changes, and macular damage. ScienceDirect

Clinical ways doctors describe it

Early or “occult” type.
In the early stage, symptoms can be mild. The pale spots may be few or subtle. Night vision and contrast may drop first. Specialized imaging (especially indocyanine green angiography and electroretinography) may pick up disease before the fundus looks classic.

Classic birdshot pattern type.
This is the well-known type with many cream-colored, oval spots in the mid-periphery. The spots often radiate toward the optic disc. Leakage on fluorescein angiography and abnormal electroretinography are common.

Macular-edema–predominant type.
Some patients mainly have central retinal swelling (cystoid macular edema). Vision becomes blurry and distorted. OCT imaging shows fluid in the macula. Treating the swelling is key to saving vision.

Vasculitic-predominant type.
Some patients show stronger inflammation of retinal vessels. Fluorescein angiography shows vessel wall staining and leakage. Patients notice floaters, glare, and reduced contrast.

ERG-abnormality–predominant type.
In some cases the main finding is a reduced or delayed electroretinogram, especially the 30-Hz cone flicker response. Patients notice problems with flicker, contrast, and night vision.

Quiescent vs. active type.
Doctors also describe the disease as active (ongoing inflammation, new leakage, new spots, or worse ERG) or quiescent (quiet). Activity guides treatment.

Unilateral-appearing vs. bilateral type.
The disease is almost always bilateral. Rarely, it may look one-sided at first, but careful testing usually finds changes in the fellow eye as well.

---

Causes

The true cause is not fully known. Doctors believe it is an autoimmune disease. The body’s immune system attacks eye tissues by mistake. Below are the most discussed contributors or risk links. They are associations and theories, not proven direct causes in every person.

1. Genetic predisposition (HLA-A29).
   Most patients carry the HLA-A29 tissue type, especially the A*29:02 subtype. This gene variant raises risk but does not guarantee disease. It likely changes how the immune system presents retinal or choroidal proteins to T-cells.

2. Autoimmune T-cell response.
   Research suggests T-cells react to antigens in the retina or choroid. These activated cells drive inflammation, damage pigment cells, and disturb retinal function.

3. Molecular mimicry after infections.
   A past infection may show the immune system a protein that looks like an eye protein. Later, the immune system “mixes them up” and attacks the eye. This is a theory used to explain many autoimmune conditions.

4. Local choroidal antigen exposure.
   Damage to the choroid or retinal pigment epithelium may expose hidden antigens. Once exposed, the immune system may target them. This can keep inflammation going.

5. Innate immune activation.
   Activation of early immune pathways (like complement or innate cytokines) may start or amplify inflammation. This can turn a small trigger into a larger, long-lasting response.

6. Cytokine imbalance.
   Too much pro-inflammatory cytokine (for example, IL-17, TNF-alpha) and too little regulatory cytokine (like IL-10) can tilt the system toward chronic inflammation.

7. Genetic background beyond HLA.
   Other genes likely affect risk (immune regulation, antigen processing, complement). They are still being studied.

8. Age-related immune drift.
   Most patients present in midlife. With age, immune control can drift, and tolerance can weaken, which may allow autoimmunity to appear.

9. Hormonal influences.
   Some autoimmune diseases vary with hormones. Subtle hormonal shifts might influence risk or activity, though data are limited in this specific condition.

10. Environmental exposures.
    Unknown environmental factors may act as co-triggers. These could include infections, pollutants, or allergens. Evidence is not strong for any single exposure.

11. Microbiome imbalance.
    The gut microbiome shapes immunity. Changes in gut bacteria may influence eye autoimmunity. This is an emerging area of research.

12. Prior systemic inflammation.
    A strong systemic inflammatory event might “prime” the immune system. In a primed state, it may react to eye antigens more easily.

13. Stress and immune dysregulation.
    Chronic stress can affect immune control. It may not cause the disease, but it can worsen flares in some people.

14. Coexisting autoimmune diseases.
    People with one autoimmune condition sometimes develop another. The shared immune traits may increase risk.

15. Viral “hit and run.”
    A virus could trigger the first misdirected immune attack, then leave. The immune system continues the damage even after the virus is gone. This is a hypothesis.

16. Genetic ancestry patterns.
    The disease has been reported more in people of certain ancestries (for example, European ancestry) where HLA-A29 is more common. This reflects genetic distribution rather than a lifestyle cause.

17. Immune checkpoint variation.
    Small differences in the molecules that “brake” the immune system (checkpoints) might make self-tolerance weaker, allowing an autoimmune attack.

18. Complement pathway effects.
    Abnormal complement activity is tied to several retinal diseases. It may also contribute here by damaging pigment cells or vessels.

19. Retinal pigment epithelium vulnerability.
    If these cells are more fragile, they may release signals that attract immune cells, starting a cycle of inflammation and pigment loss.

20. Unknown co-factors.
    There may be more co-factors we do not know yet. Research continues to search for triggers and protective factors.

---

Symptoms

1. Blurry vision.
   Vision may be hazy, especially when the macula swells. Reading and fine detail become harder.

2. Floaters.
   You may see small moving spots or cobwebs. These come from inflammatory cells in the vitreous gel.

3. Trouble seeing at night (nyctalopia).
   Dark places feel much darker. Adjusting from light to dark takes longer. This reflects retinal dysfunction.

4. Problems with contrast.
   Gray shades are harder to tell apart. Faces and text look washed out, even when the chart letters seem okay.

5. Color fading.
   Colors can look less bright. Some people notice blues and greens change the most.

6. Glare and light sensitivity.
   Bright lights feel harsh. Sunlight and headlights may bother the eyes.

7. Wavy or distorted lines (metamorphopsia).
   Straight lines look bent or shaky. This points to macular swelling or damage.

8. Flashes or sparks (photopsias).
   You may notice brief lights, especially in dim conditions. These relate to irritated or mis-firing retinal cells.

9. Paracentral blind spots.
   Small missing areas appear near the center of vision. Reading can be patchy or tiring.

10. Peripheral field defects.
    Side vision may shrink a bit. Confrontation field tests can pick this up.

11. Slow dark adaptation.
    After turning off a light, it takes longer than usual to see in the dark. This ties to rod system dysfunction.

12. Difficulty with flicker or fast movement.
    Things that flicker or move fast become harder to detect. ERG often shows delayed cone flicker.

13. Eye discomfort (usually mild).
    This is not a very painful disease. Discomfort is usually from inflammation or dry eye, not severe pain.

14. Headache or eye strain.
    These occur from trying to focus or read with poor contrast or distorted vision.

15. Reading fatigue.
    Small print is tiring. People take frequent breaks or increase lighting and font size.

---

Diagnostic tests

Physical exam

1. Best-corrected visual acuity.
   You read letters on a chart with the best glasses correction. This measures how clearly you see. It helps track changes over time and the effect of macular swelling.

2. Color vision testing.
   Simple plates (like Ishihara) or advanced color tests check color loss. Subtle color changes often happen early in this disease.

3. Amsler grid.
   This is a small grid you look at at reading distance. Wavy lines or missing squares suggest macular changes, such as swelling.

4. Confrontation visual fields.
   Your doctor checks side vision by wiggling fingers from the edges. It can reveal field defects from retinal dysfunction.

Manual clinical tests

5. Pupil exam for relative afferent defect.
   The doctor swings a light between eyes to see if one pupil reacts less. A subtle defect suggests reduced retinal/optic nerve function.

6. Tonometry (eye pressure).
   Measuring eye pressure helps rule out pressure-related problems and checks safety before dilating or treating.

7. Slit-lamp biomicroscopy.
   This microscope exam looks for inflammatory cells in the front part of the eye and in the vitreous. It also checks for lens changes and other causes of blur.

8. Dilated indirect ophthalmoscopy with a 90D lens.
   After dilation, the doctor inspects the retina and choroid. In birdshot, they see multiple cream-colored oval spots and may see vessel inflammation.

Lab and pathological tests

9. HLA-A29 typing.
   A blood test checks for the HLA-A29 tissue type. Most patients are positive. A positive result supports the diagnosis when the clinical picture fits. A negative result suggests looking for other causes.

10. Syphilis serology (RPR/VDRL and treponemal test).
    Syphilis can mimic many posterior uveitis conditions. Negative tests help exclude an infectious look-alike.

11. Tuberculosis testing (IGRA or TST) and chest imaging.
    TB can also cause posterior uveitis. These tests help rule it out, especially in areas where TB is more common.

12. Sarcoidosis screen (serum ACE/lysozyme ± chest imaging).
    Sarcoid can affect the eye and copy some signs. These labs and imaging help exclude it in the right clinical setting.

13. Autoimmune panel (e.g., ANA, ANCA, rheumatoid factor).
    These tests do not diagnose birdshot directly but help rule out other autoimmune uveitides that can look similar.

Electrodiagnostic tests

14. Full-field electroretinography (ERG).
    This test measures the electrical signal of the whole retina in dark and light conditions. In birdshot, cone responses (30-Hz flicker) are often delayed and reduced, and rod responses can be abnormal. ERG helps detect disease early and track it over time.

15. Multifocal ERG.
    This test maps electrical signals from many small retinal areas. It can find patchy dysfunction near the macula that matches symptoms like paracentral scotomas.

16. Electro-oculography (EOG).
    EOG assesses the function of the retinal pigment epithelium. Abnormal results support diffuse outer retinal/RPE dysfunction.

Imaging tests

17. Optical coherence tomography (OCT).
    OCT is like an optical ultrasound. It shows cross-sections of the retina. It detects cystoid macular edema, thinning, or disruption of photoreceptor layers. It is essential for monitoring treatment.

18. Fluorescein angiography (FA).
    A dye is injected into a vein, and photos are taken as it passes through retinal vessels. FA shows vessel leakage, optic disc leakage, and macular edema. It helps measure how active the inflammation is.

19. Indocyanine green angiography (ICGA).
    This dye highlights the choroidal circulation. In birdshot, ICGA shows many dark hypofluorescent spots that can be more numerous than what the doctor sees by looking alone. ICGA is very helpful because this is a choroidal disease.

20. Fundus autofluorescence (FAF).
    This camera sees natural signals from lipofuscin in the retinal pigment epithelium. Areas of damage show as bright or dark patterns. FAF maps the health of the pigment layer over time.

Non-pharmacological treatments (therapies & others)

Each item includes a brief description, purpose, and mechanism. These support—but do not replace—medical treatment.

1. Regular specialist follow-up with uveitis/retina clinic
   Description: Ongoing care with a uveitis-trained ophthalmologist is essential. Visits usually include visual acuity, intraocular pressure, dilated exam, optical coherence tomography (OCT), and sometimes wide-field photos and visual fields. The plan adjusts based on inflammation control and steroid side effects.
   Purpose: Catch flares early, tailor therapy, and prevent macular damage.
   Mechanism: Frequent monitoring detects fluid, cystoid macular edema, or optic nerve changes, so therapy can be intensified or tapered promptly. (General uveitis standards from clinical reviews.) PMC

2. Optical coherence tomography (OCT)-guided care
   Description: OCT is a painless scan that shows micrometer-level layers of the retina. It reveals swelling, cysts, subretinal fluid, and atrophy.
   Purpose: Early detection of macular edema and monitoring response.
   Mechanism: Quantifies retinal thickness and edema so treatments can be timed and dosed precisely. PMC

3. Ultra-widefield imaging & fundus autofluorescence when needed
   Description: Wide-field images map the classic “birdshot” lesions and peripheral inflammation; autofluorescence highlights retinal pigment epithelium stress.
   Purpose: Document disease spread, track lesions over time.
   Mechanism: Objective imaging of inflammatory footprints to guide therapy intensity. EyeWiki

4. Electrophysiology (ERG) for functional monitoring
   Description: Full-field or multifocal ERG measures retinal function and may track photoreceptor stress in birdshot.
   Purpose: Detect functional loss not obvious on exam.
   Mechanism: Records electrical responses of retina, complementing structure-based tests. NCBI

5. Blue-light and UV protection
   Description: Sunglasses with UV/blue-light filtering can reduce light sensitivity and glare.
   Purpose: Comfort and potential reduction in photic stress when the macula is irritable.
   Mechanism: Lowers retinal light load during active inflammation.

6. Smoking cessation
   Description: Smoking worsens ocular microcirculation and increases oxidative stress.
   Purpose: Support retinal health and lower inflammation burden.
   Mechanism: Reduces vasoconstriction and toxin exposure that can aggravate uveitis.

7. Sleep, stress, and circadian regularity
   Description: Chronic stress and poor sleep can worsen inflammatory pathways.
   Purpose: Support immune balance and steroid-sparing goals.
   Mechanism: Better cortisol rhythm and reduced sympathetic drive may blunt flare propensity.

8. Vaccination planning (with the treating team)
   Description: Before systemic immunosuppression, appropriate, non-live vaccinations may be timed. Live vaccines are generally avoided during significant immunosuppression.
   Purpose: Reduce infection risk while on therapy.
   Mechanism: Pre-emptive immune protection lowers serious infection complications.

9. Bone health measures during steroid use
   Description: Calcium, vitamin D through diet, weight-bearing exercise, and DEXA when appropriate.
   Purpose: Prevent osteoporosis from systemic or repeated steroid exposure.
   Mechanism: Supports bone remodeling and counters steroid-related bone loss.

10. Blood pressure, glucose, and lipid control
    Description: Manage cardiovascular risks that can worsen retinal perfusion and steroid side effects.
    Purpose: Protect retina and overall health.
    Mechanism: Stabilizes microvascular function under inflammatory stress.

11. Anti-inflammatory diet pattern
    Description: Emphasize colorful vegetables, omega-3-rich fish, whole grains, legumes, nuts; limit ultra-processed foods.
    Purpose: Lower systemic inflammatory tone.
    Mechanism: Improves omega-3/omega-6 balance and antioxidant intake.

12. Gentle physical activity
    Description: Regular walking or low-impact exercise supports immune health and mood.
    Purpose: Reduce systemic inflammation and steroid-related weight gain.
    Mechanism: Exercise releases anti-inflammatory myokines.

13. Dry-eye relief if present
    Description: Preservative-free tears, lid hygiene, and environmental adjustments.
    Purpose: Improve comfort and vision quality.
    Mechanism: Stabilizes tear film and reduces surface irritation that magnifies glare.

14. Glaucoma surveillance
    Description: Steroids (drops/implants/systemic) can raise eye pressure.
    Purpose: Prevent optic nerve damage.
    Mechanism: Periodic IOP checks and timely pressure-lowering measures. (Steroid label warnings). FDA Access Data+1

15. Cataract counseling
    Description: Long steroid exposure increases cataract risk.
    Purpose: Plan for timing of surgery if vision-limiting cataract develops.
    Mechanism: Patient education speeds referral when needed. FDA Access Data

16. Infection-risk education on immunosuppression
    Description: Hand hygiene, food safety, and early reporting of fevers.
    Purpose: Lower severe infection risk on biologics or antimetabolites.
    Mechanism: Behavioral risk reduction + prompt evaluation. (Biologic/antimetabolite labels). FDA Access Data+1

17. Family/workplace lighting and contrast tweaks
    Description: Better ambient light, high-contrast settings, and screen adjustments.
    Purpose: Reduce eye strain and improve reading/working comfort.
    Mechanism: Optimizes visual ergonomics during recovery.

18. Low-vision aids if needed
    Description: Magnifiers, high-contrast materials, and digital enlargement tools.
    Purpose: Maintain independence if central vision is affected.
    Mechanism: Enhances residual vision function.

19. Psychological support
    Description: Chronic eye disease affects mood and quality of life.
    Purpose: Reduce anxiety/depression that may worsen adherence.
    Mechanism: Counseling and support groups build coping skills.

20. Flare action plan
    Description: Clear steps if symptoms worsen (whom to call, urgent visit triggers).
    Purpose: Speed treatment during relapses.
    Mechanism: Early intervention limits retinal damage.

---

Drug treatments

Notes: Doses below reflect typical adult regimens used in noninfectious posterior uveitis; birdshot often requires combination therapy. Exact dosing, timing, and monitoring must be individualized by a uveitis specialist. Off-label systemic immunomodulators are common in birdshot; FDA labels are cited to support safety profiles/indications where applicable.

1. Adalimumab (Humira and adalimumab biosimilars)
   Class: TNF-α inhibitor (biologic).
   Typical adult dosing/time: 80 mg SC once, then 40 mg SC every other week starting 1 week later (uveitis label).
   Purpose: Control chronic noninfectious intermediate, posterior, or panuveitis; reduce steroid needs.
   Mechanism: Blocks TNF-α, a key inflammatory signal in uveitis.
   Side effects: Injection-site reactions, infections (including serious), TB reactivation risk, rare demyelination; requires infection screening and monitoring. (FDA uveitis label.) FDA Access Data

2. Dexamethasone intravitreal implant (Ozurdex)
   Class: Corticosteroid implant (0.7 mg).
   Dose/time: Single office-based intravitreal implant; may be repeated per specialist judgment.
   Purpose: Rapid control of posterior segment inflammation and macular edema.
   Mechanism: Potent local steroid suppresses cytokines and edema.
   Side effects: IOP rise, cataract progression, infection risk; avoid with active ocular infection. (FDA label.) FDA Access Data+1

3. Fluocinolone acetonide intravitreal implant (Yutiq 0.18 mg)
   Class: Long-acting corticosteroid implant (≈36 months).
   Dose/time: Single intravitreal implant delivering ~0.25 µg/day.
   Purpose: Maintain long-term control and reduce relapses.
   Mechanism: Continuous local steroid release to keep inflammation quiet.
   Side effects: IOP elevation, glaucoma procedures, cataract; infection risk. (FDA NDA label + summary review.) FDA Access Data+1

4. Fluocinolone acetonide intravitreal implant (Retisert 0.59 mg)
   Class: Surgically placed corticosteroid implant (≈2.5–3 years).
   Dose/time: Operating-room placement; sustained micro-release.
   Purpose: Durable control in recurrent/relentless disease.
   Mechanism: Long-term local steroid delivery.
   Side effects: High IOP, need for glaucoma surgery, cataract almost universal, infection risk. (FDA label/approval docs.) FDA Access Data+1

5. Prednisone (oral)
   Class: Systemic corticosteroid.
   Dose/time: Often 0.5–1 mg/kg/day for induction, then careful taper; lowest effective maintenance if needed.
   Purpose: Rapid, whole-eye anti-inflammatory control.
   Mechanism: Broad cytokine suppression.
   Side effects: Weight gain, mood change, glucose and BP elevation, osteoporosis, cataract, glaucoma, infection risk; taper to avoid adrenal crisis. (Representative FDA labeling for prednisone products.) FDA Access Data+1

6. Prednisolone acetate ophthalmic (e.g., Pred Forte / Omnipred)
   Class: Topical corticosteroid drop.
   Dose/time: Typically used adjunctively for anterior spillover; frequency per activity.
   Purpose: Calm anterior segment inflammation when present.
   Mechanism: Local steroid anti-inflammatory effect.
   Side effects: IOP rise, cataract with prolonged use. (FDA labels.) FDA Access Data+1

7. Triamcinolone acetonide (periocular/intravitreal use off-label; Kenalog products)
   Class: Depot corticosteroid suspension.
   Dose/time: Sub-Tenon/periocular injection per specialist; intravitreal use has safety warnings in some formulations.
   Purpose: Short- to medium-term local control and macular edema reduction.
   Mechanism: Local steroid depot.
   Side effects: IOP spikes, cataract, infection; heed product-specific warnings on ocular routes. (FDA labels.) FDA Access Data+1

8. Mycophenolate mofetil (CellCept)
   Class: Antimetabolite immunosuppressant.
   Dose/time: Commonly 1–1.5 g twice daily orally (off-label for uveitis).
   Purpose: Steroid-sparing maintenance control.
   Mechanism: Inhibits inosine monophosphate dehydrogenase → reduces lymphocyte proliferation.
   Side effects: GI upset, leukopenia, infection risk; contraception needed due to teratogenicity concerns. (FDA label for safety profile.) FDA Access Data

9. Azathioprine (Imuran)
   Class: Purine analog immunosuppressant.
   Dose/time: Often ~1–2 mg/kg/day (off-label for uveitis).
   Purpose: Steroid-sparing control when antimetabolites are chosen.
   Mechanism: Inhibits DNA synthesis in rapidly dividing immune cells.
   Side effects: Bone-marrow suppression, infection risk, malignancy warnings; TPMT/NUDT15 status can influence risk. (FDA label.) FDA Access Data

10. Methotrexate (oral or subcutaneous)
    Class: Antimetabolite (folate antagonist).
    Dose/time: Weekly dosing (e.g., 10–25 mg once weekly) with folic acid; not daily.
    Purpose: Steroid-sparing control; widely used in uveitis.
    Mechanism: Anti-proliferative and anti-inflammatory effects on T-cells and cytokines.
    Side effects: Hepatotoxicity, cytopenias, mouth sores; strict monitoring and pregnancy avoidance needed. (FDA methotrexate tablet labeling.) FDA Access Data

11. Cyclosporine (Neoral/Sandimmune)
    Class: Calcineurin inhibitor.
    Dose/time: Dosing individualized; often split twice daily with drug-level/creatinine/BP monitoring.
    Purpose: Steroid-sparing agent when T-cell suppression is desired.
    Mechanism: Blocks calcineurin → reduces IL-2 and T-cell activation.
    Side effects: Nephrotoxicity, hypertension, tremor, gum overgrowth, infections; require close monitoring. (FDA labels.) FDA Access Data+1

12. Infliximab (Remicade)
    Class: TNF-α inhibitor (IV infusion).
    Dose/time: Common regimens start at 3–5 mg/kg IV at 0, 2, and 6 weeks, then every 4–8 weeks; often combined with an antimetabolite to reduce antibodies.
    Purpose: Control severe or refractory inflammation.
    Mechanism: Neutralizes soluble and membrane TNF-α.
    Side effects: Infusion reactions, serious infections, TB reactivation; malignancy warnings. (FDA label.) FDA Access Data

13. Periocular/Intravitreal steroids as bridge therapy
    Class: Local corticosteroids (e.g., triamcinolone, dexamethasone implant).
    Dose/time: Single injections or implants with repeat as needed.
    Purpose: Rapid macular edema and posterior inflammation control while systemic agents take effect.
    Mechanism: Concentrated local steroid action.
    Side effects: IOP and cataract risks; infection precautions. (FDA steroid labels.) FDA Access Data

14. Prednisolone oral (systemic alternative to prednisone)
    Class: Systemic corticosteroid.
    Dose/time: Similar to prednisone; active metabolite with equivalent anti-inflammatory effect.
    Purpose/Mechanism/Side effects: As above for systemic steroids. (Representative FDA labeling.) FDA Access Data

15. Adalimumab biosimilars (e.g., HULIO)
    Class: TNF-α inhibitor biosimilar.
    Dose/time: Same uveitis dosing strategy as reference adalimumab.
    Purpose/Mechanism/Side effects: Equivalent TNF-α blockade; similar safety class effects. (FDA biosimilar label.) FDA Access Data

16. Topical cycloplegics (supportive)
    Class: Antimuscarinic drops (e.g., homatropine) when anterior spillover is present.
    Dose/time: As needed to relieve ciliary spasm.
    Purpose: Pain relief and prevention of posterior synechiae.
    Mechanism: Temporarily relaxes ciliary muscle and dilates pupil. (General uveitis practice in reviews.) NCBI

17. Prophylactic gastric and bone protection when on steroids
    Class: PPIs/H2 blockers; calcium/vitamin D; sometimes bisphosphonates per risk.
    Purpose: Reduce steroid complications.
    Mechanism: Protects GI mucosa and bone remodeling; clinician-directed.

18. IOP-lowering drops for steroid responders
    Class: Prostaglandin analogs, beta-blockers, CAIs, alpha-agonists as appropriate.
    Purpose: Treat steroid-induced ocular hypertension.
    Mechanism: Increase aqueous outflow or reduce production; tailored to patient.

19. ACTH (Repository corticotropin injection, H.P. Acthar Gel)
    Class: Endogenous ACTH analog.
    Dose/time: Specialist-directed; evidence is limited in uveitis and not first-line for birdshot.
    Purpose: Alternative anti-inflammatory pathway when other options fail or are unsuitable.
    Mechanism: Stimulates adrenal steroidogenesis and melanocortin pathways.
    Side effects: Similar steroid-type effects, edema, glucose rise, infection risk. (FDA label.) FDA Access Data+1

20. Rescue therapy combinations (biologic + antimetabolite)
    Class: TNF-α inhibitor combined with methotrexate or mycophenolate.
    Purpose: Improve durability and reduce anti-drug antibodies.
    Mechanism: Dual suppression of inflammatory pathways. (Infliximab label notes lower antibody/infusion reaction with concomitant immunosuppression.) FDA Access Data

---

Dietary molecular supplements (supportive, not curative)

Important: supplements should be coordinated with your clinician, especially if you take immunosuppressants or blood thinners.

1. Omega-3 fatty acids (EPA/DHA)
   Description (~150 words): Marine omega-3s help balance pro- and anti-inflammatory lipid mediators. In retinal disease, they may support photoreceptor membranes and reduce inflammatory signaling. They are food-first (fatty fish) with supplements as needed.
   Dosage: Often 1–2 g/day combined EPA+DHA with meals.
   Function: Anti-inflammatory lipid mediators; possible macular support.
   Mechanism: Competes with arachidonic-acid pathways to generate resolvins/protectins.

2. Lutein + Zeaxanthin
   Description: Macular carotenoids that concentrate in the fovea and may support contrast sensitivity and glare recovery.
   Dosage: Commonly 10 mg lutein + 2 mg zeaxanthin/day.
   Function: Macular pigment support and antioxidant effects.
   Mechanism: Blue-light filtering and reactive-oxygen quenching.

3. Vitamin D
   Description: Low vitamin D is linked with dysregulated immunity in several autoimmune conditions. Correcting deficiency may help overall immune balance.
   Dosage: Per labs; many adults need 1000–2000 IU/day, adjusted by clinician.
   Function: Immune modulation.
   Mechanism: Influences T-reg cell activity and cytokine profile.

4. Curcumin (with piperine or formulated for absorption)
   Description: Plant polyphenol with anti-NF-κB effects; preliminary ocular/uveitis research suggests symptom relief in some contexts.
   Dosage: Often 500–1000 mg/day standardized extract (bioavailability-enhanced).
   Function: Adjunct anti-inflammatory.
   Mechanism: Down-regulates pro-inflammatory transcription factors.

5. Resveratrol
   Description: Polyphenol with antioxidant and SIRT-related signaling effects.
   Dosage: 100–250 mg/day in divided doses.
   Function: Systemic antioxidant support.
   Mechanism: Modulates oxidative stress and inflammation cascades.

6. Quercetin
   Description: Flavonoid with mast-cell stabilizing and anti-inflammatory properties.
   Dosage: 250–500 mg once or twice daily.
   Function: Adjunct symptom support.
   Mechanism: Inhibits histamine release and NF-κB activation.

7. N-Acetylcysteine (NAC)
   Description: Precursor to glutathione, the body’s key antioxidant; may support retinal oxidative defenses.
   Dosage: 600–1200 mg/day.
   Function: Antioxidant replenishment.
   Mechanism: Boosts intracellular glutathione and scavenges oxidants.

8. Alpha-lipoic acid
   Description: Redox-active antioxidant working in fat and water phases; supports mitochondria.
   Dosage: 300–600 mg/day.
   Function: Antioxidant cofactor.
   Mechanism: Regenerates other antioxidants; modulates NF-κB.

9. Coenzyme Q10 (Ubiquinone/Ubiquinol)
   Description: Mitochondrial cofactor aiding photoreceptor energy needs.
   Dosage: 100–200 mg/day (formulation dependent).
   Function: Mitochondrial support.
   Mechanism: Electron transport participation; antioxidant effect.

10. Probiotics (evidence-emerging)
    Description: Gut–eye axis research suggests microbiome balance can shape systemic immunity.
    Dosage: Product-specific (often 10–20 billion CFU/day of mixed lactobacillus/bifidobacterium).
    Function: Immune modulation.
    Mechanism: Tight-junction support, T-reg promotion, and reduced endotoxin signaling.

---

Drugs for immunity booster / regenerative / stem-cell” angles

Note: There are no approved stem-cell drugs for birdshot. The items below are immune-modulating or regenerative-leaning concepts used adjunctively or studied in uveitis.

1. Adalimumab (immune modulation)
   Description (~100 words): Biologic TNF-α blockade can “reset” an overactive inflammatory loop, allowing steroid tapering and vision preservation in noninfectious posterior uveitis.
   Dosage: 80 mg SC once, then 40 mg every other week.
   Function: Potent immune dampener.
   Mechanism: TNF-α inhibition reduces downstream cytokine networks. FDA Access Data

2. Mycophenolate mofetil
   Description: Antimetabolite that selectively limits lymphocyte proliferation, often used long-term to maintain remission.
   Dosage: Typically 1–1.5 g twice daily.
   Function: Steroid-sparing maintenance.
   Mechanism: Inhibits guanine synthesis in B/T cells. FDA Access Data

3. Methotrexate (low-dose weekly)
   Description: Dampens T-cell activity and inflammatory mediators at low weekly doses; widely used in autoimmune eye disease.
   Dosage: 10–25 mg once weekly with folic acid.
   Function: Immunomodulatory maintenance.
   Mechanism: Folate antagonist with anti-cytokine effects. FDA Access Data

4. Cyclosporine
   Description: Calcineurin inhibitor that targets T-cell activation; useful when TNF-blockade or antimetabolites are unsuitable.
   Dosage: Individualized, divided BID with drug-level monitoring.
   Function: Powerful T-cell suppression.
   Mechanism: Blocks IL-2 transcription via calcineurin inhibition. FDA Access Data

5. Fluocinolone acetonide implant (Yutiq/Retisert)
   Description: Long-acting intraocular steroid delivery that can stabilize inflammation for years and limit systemic exposure.
   Dosage: Single implant (0.18 mg Yutiq; 0.59 mg Retisert).
   Function: Local sustained anti-inflammatory effect.
   Mechanism: Continuous corticosteroid release in vitreous cavity. FDA Access Data+1

6. Repository corticotropin injection (H.P. Acthar Gel)
   Description: Stimulates adrenal steroid release and engages melanocortin receptors; niche role in refractory cases under specialist guidance.
   Dosage: Specialist-directed protocols.
   Function: Alternative anti-inflammatory pathway.
   Mechanism: ACTH-mediated steroidogenesis and melanocortin immunomodulation. FDA Access Data

Surgeries/procedures

1. Fluocinolone implant placement (Retisert)
   Procedure: Surgical placement of a tiny steroid implant through the sclera into the vitreous.
   Why done: Long-term control in patients with frequent relapses or steroid dependence. (FDA docs.) FDA Access Data

2. Intravitreal steroid implant injection (Ozurdex, Yutiq)
   Procedure: Office-based injection using a preloaded applicator after antisepsis and local anesthesia.
   Why done: Rapid and sustained local steroid effect for posterior uveitis and macular edema. (FDA labels.) FDA Access Data+1

3. Glaucoma surgery (if steroid-induced IOP uncontrolled)
   Procedure: Laser or filtering surgeries (e.g., trabeculectomy, drainage device).
   Why done: Protect optic nerve when pressure remains high despite drops.

4. Cataract extraction
   Procedure: Phacoemulsification with intraocular lens placement.
   Why done: Restore clarity when steroid-related or disease-related cataract reduces vision.

5. Pars plana vitrectomy (selected cases)
   Procedure: Removal of vitreous gel causing dense floaters or traction; allows better drug access.
   Why done: Improve vision quality or manage complications.

---

Preventions

1. Timely treatment and no “drug holidays” without specialist advice.

2. Vaccination planning before immunosuppression; avoid live vaccines during strong suppression.

3. TB/hepatitis screening before TNF-blockade or other potent agents.

4. Infection precautions (hand hygiene, rapid evaluation of fever/cough).

5. Monitor IOP regularly during/after steroid therapies.

6. Bone and metabolic health measures during systemic steroid use.

7. Smoking cessation and minimize second-hand smoke.

8. Adherence aids (pill boxes, reminders) to avoid flares from missed doses.

9. Sun/blue-light protection and anti-glare strategies.

10. Written flare plan with urgent contact instructions.

---

When to see a doctor (red flags)

• Sudden drop in vision, new central blur, distortion, or dark curtain.

• New or rapidly worsening floaters or flashes of light.

• Eye pain, severe redness, or marked light sensitivity.

• Home BP or glucose spikes while on steroids.

• Headache, fever, or cough while on biologics or antimetabolites.

• Medication side effects such as jaundice, severe fatigue, mouth ulcers, easy bruising, shortness of breath, or leg swelling.

• Any pregnancy or planning discussions if you use teratogenic drugs (e.g., methotrexate, mycophenolate). (Safety per FDA labels.) FDA Access Data+1

---

What to eat and what to avoid

Eat more:

1. Fatty fish (salmon, sardines) 2–3 times/week (omega-3s).

2. Colorful vegetables and fruits daily (antioxidants).

3. Nuts/seeds and olive oil (healthy fats).

4. Whole grains and legumes (fiber for gut–immune axis).

5. Fermented foods or a clinician-approved probiotic.

Limit/avoid:

1. Ultra-processed snacks high in refined sugars.
2. Excess omega-6 seed-oil-heavy fried foods.
3. Excess alcohol (interacts with methotrexate; liver risk).
4. Grapefruit with certain drugs (e.g., cyclosporine) per label guidance. FDA Access Data
5. Unpasteurized/raw foods and buffets when heavily immunosuppressed (infection risk).

---

Frequently asked questions

1) Is birdshot chorioretinopathy contagious?
No. It is an autoimmune eye condition and cannot be caught from others. (Reviews.) PMC

2) Will I lose my vision?
Many people keep useful vision with early diagnosis, steady follow-up, and the right mix of local and systemic treatments; delays increase risk. (Reviews.) NCBI

3) Why do doctors talk about HLA-A29?
Birdshot is strongly associated with HLA-A29; absence can push doctors to recheck the diagnosis if the picture is unclear. NCBI

4) Why are implants used instead of drops?
The inflammation is deep in the back of the eye; implants deliver steroid right where it is needed for months to years. (FDA labels.) FDA Access Data+1

5) Are biologics safe?
They are effective but carry infection risks; screening and monitoring reduce danger. (Adalimumab/infliximab labels.) FDA Access Data+1

6) How long will I need treatment?
Birdshot can smolder for years. Plans are personalized and often include a slow, careful taper after stable control. (Reviews.) PMC

7) Can diet cure birdshot?
No. Diet supports general health and inflammation balance but does not replace medicines. Use it as an adjunct.

8) Are steroid drops enough?
Usually not, because the disease sits in the posterior segment; drops help if anterior inflammation appears but are rarely adequate alone. (Uveitis practice.) NCBI

9) What is macular edema and why is it serious?
It’s fluid in the central retina that blurs vision; implants or systemic therapy often target it urgently. (FDA steroid implant labels.) FDA Access Data

10) Will I need glaucoma or cataract surgery?
Possibly, especially after long steroid exposure; IOP checks and cataract counseling are routine. (Steroid labels.) FDA Access Data

11) Can I get vaccinated while on treatment?
Yes for non-live vaccines; live vaccines are generally avoided with significant immunosuppression—coordinate timing with your team.

12) Is pregnancy safe on these drugs?
Some agents (methotrexate, mycophenolate) are unsafe; contraception and pre-conception planning with your specialist are vital. (FDA labels.) FDA Access Data+1

13) How do doctors pick between methotrexate, mycophenolate, or cyclosporine?
They look at your health history, lab tolerance, side-effect profiles, and how your eyes respond over time. (Reviews + labels.) PMC

14) What if adalimumab is not enough?
Options include dose interval changes, adding an antimetabolite, or switching to another biologic or a long-acting implant, depending on the case. (Clinical practice patterns; infliximab label on combo use.) FDA Access Data

15) Can stress cause a flare?
Stress does not cause birdshot, but it can affect sleep and immune balance; stress management supports overall control.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 27, 2025.